You are here: Home > Sectors

29/10/2020 03:59pm

PLI schemes revised to promote domestic production of bulk drugs and medical devices

image PLI schemes revised to promote domestic production of bulk drugs and medical devices

New Delhi, Oct 29 (KNN) After receiving several suggestions and comments received fr0m the industry, the Union Department of Pharmaceuticals under Ministry of Chemicals and fertilizers on Thursday revised the Production Linked Incentive (PLI) Schemes for promoting domestic manufacturing of bulk drugs and medical devices.

Accordingly, the ‘minimum threshold’ investment requirement has been replaced by ‘committed investment’ taking into account availability of technology choices which varies fr0m product to product.

The Department of Pharmaceuticals earlier had come out with two Production Linked Incentive schemes: one for promotion of domestic manufacturing of critical Key Starting Materials, Drug Intermediates and Active Pharmaceutical Ingredients in India and another for promoting domestic manufacturing of medical devices.

Both the schemes were approved by the Cabinet on March 20, 2020, and the detailed guidelines for the implementation of the schemes were issued by the Department on July 27, 2020.

Post issuance of the detailed guidelines, the department received several suggestions and inputs fr0m the pharmaceutical and medical device industry seeking certain amendments in the scheme to enable effective participation of the industry in the two schemes.

The recommendations of the technical committees were placed before the empowered committees of the schemes which are chaired by CEO NITI Aayog.

After considering the recommendations of the technical committees, the EC approved the revision of the guidelines for both the schemes. Accordingly, the revised guidelines have been issued today viz 29.10.2020 and are available on the website of the Department of Pharmaceuticals under the tab “schemes”.

The main changes which have been affected in the revised guidelines for Production Linked Incentive (PLI) scheme for promotion of domestic manufacturing of critical Key Starting Materials, Drug Intermediates and Active Pharmaceutical Ingredients in India are:

  -- 1. Replacement of the criteria of ‘minimum threshold’ investment with ‘committed’ investment by the selected applicant. The change has been made to encourage efficient use of productive capital as the amount of investment required to achieve a particular level of production depends upon choice of technology and it also varies fr0m product to product. The provision for verification of the actual investment made by the selected applicant for the purpose of giving incentives under the scheme continues.

  -- Deletion of the provision which restricts the sales of eligible products to domestic sales only, for the purpose of eligibility of receiving incentives, bringing the scheme in line with other PLI schemes and encouraging market diversification.

  -- Change in the minimum annual production capacity for 10 products viz Tetracycline, Neomycin, Para Amino Phenol (PAP), Meropenem, Artesunate, Losartan, Telmisartan, Acyclovir, Ciprofloxacin and Aspirin. Minimum annual production capacity is a part of eligibility criteria under the scheme.

The last date for receiving applications under the scheme is now extended by a week to November 30, 2020 (inclusive). The main changes which have been affected in the revised guidelines for Production Linked Incentive Scheme for Promoting Domestic Manufacturing of Medical Devices include:

  -- Replacement of the criteria of ‘minimum threshold’ investment with ‘committed’ investment by the selected applicant. The change has been made to encourage efficient use of productive capital as the amount of investment required to achieve a particular level of production depends upon technology used and it also varies fr0m product to product. The provision for verification of the actual investment made by the selected applicant for the purpose of giving incentives under the scheme continues.

  -- Change in the eligibility criteria of minimum sales threshold in line with projected demand, technology trend and market development, for the purpose of availing incentive under the scheme.

  -- The tenure of the scheme has been extended by one year keeping in view the capital expenditure expected to be done by the selected applicants in FY 2021-22. Accordingly, the sales for the purpose of availing incentives will be accounted for 5 years starting fr0m FY 2022-2023 instead of FY 2021-2022.

  -- The last date for receiving applications under the scheme is now extended by a week to November 30, 2020 (inclusive)

It is worth noting that the Indian pharmaceutical industry is the third-largest globally in terms of volume and contributes significantly to India’s economic growth and export earnings. The Medical Devices industry is identified as a sunrise sector with great potential for diversification and employment generation.

Share

Related Articles

Comments

    Be first to give your comments.

Write a Comment

Your email address will not be published.
Required fields are marked *